Survodutide 10mg – Protide Health USA

Survodutide Peptide Overview & Technical Specifications

Survodutide, also known by the development code BI 456906, is a synthetic 29-residue acylated peptide designed as a dual agonist of the GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR).

Its molecular design is based on a modified glucagon-related peptide framework and incorporates non-standard structural elements intended to alter receptor selectivity and pharmacokinetic behavior.

The supplied Survodutide PubChem chemical record identifies the compound as PubChem CID 168429725, CAS 2805997-46-8, with molecular formula C192H289N47O61 and molecular weight approximately 4232 g/mol.

A verified shorthand representation of the modified sequence is:

H-Ac4c-QGTFTSDYSKYLDERAAKDFI-X-WLESA-NH₂

where Ac4c represents 1-aminocyclobutane-1-carboxylic acid and X represents a modified lysine-associated linker carrying a C18 di-acid moiety.

Protide Health supplies Survodutide as 10mg of 99% purity lyophilized material for biochemical, receptor-binding, metabolic-signaling, analytical, and qualified preclinical research.

Technical Specifications

• Product Name: Survodutide
• Synonym: BI 456906
• Quantity: 10mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified; third-party tested
• Peptide Length: 29 residues
• Classification: Acylated dual GLP-1R/GCGR agonist peptide
• CAS Number: 2805997-46-8
• PubChem CID: 168429725
• Molecular Formula: C192H289N47O61
• Molecular Weight: Approximately 4231.6 g/mol
• Appearance: White to off-white lyophilized powder
• Storage: Store sealed at ≤6°C and protected from heat, light, and moisture
• Research Use: Laboratory, biochemical, receptor-signaling, metabolic, and preclinical research only

Survodutide Mechanism of Action & Research Context

The survodutide mechanism of action centers on dual activation of GLP-1R and GCGR, both members of the class B G protein-coupled receptor family.

Preclinical pharmacology has demonstrated functional agonism at both receptors in cell-based systems. Activation of these receptor pathways is associated with Gs-protein signaling and intracellular cyclic AMP generation.

GLP-1R-associated experimental models have been used to investigate pancreatic signaling, nutrient-related responses, gastric-emptying pathways, and food-intake regulation.

GCGR activation has been examined through hepatic signaling, amino-acid metabolism, energy-expenditure pathways, and circulating metabolic biomarkers.

The dual-receptor activity differentiates Survodutide from compounds that predominantly target only GLP-1R.

Researchers can examine broader Survodutide and dual GLP-1/glucagon receptor research indexed by PubMed for peer-reviewed preclinical and clinical-development literature.

Preclinical Research Applications

Dual GLP-1R and GCGR Signaling

A major research focus for Survodutide is simultaneous engagement of GLP-1R and GCGR.

Preclinical studies have used recombinant cell systems, pancreatic islets, hepatocytes, knockout models, reporter animals, and other experimental platforms to distinguish activity at the two receptors.

Research endpoints have included:

• Intracellular cAMP generation
• Receptor activation
• Glucose-stimulated signaling
• Hepatic metabolic pathways
• Circulating amino-acid biomarkers
• Energy-balance pathways
• Food-intake models

These studies demonstrate dual receptor pharmacology but do not establish outcomes for independently supplied laboratory material.

GLP-1 Receptor Research

GLP-1R is a class B GPCR extensively studied in endocrine and metabolic research.

Activation of this receptor has been investigated experimentally in relation to pancreatic signaling, insulin-associated responses, nutrient sensing, gastric physiology, and central appetite-related pathways.

The survodutide peptide provides one research model for examining GLP-1R signaling alongside simultaneous glucagon-receptor activity.

Glucagon Receptor Research

GCGR signaling represents the second major component of Survodutide pharmacology.

Preclinical investigations have examined GCGR-associated effects on hepatic signaling, amino-acid metabolism, fibroblast growth factor-21-associated biomarkers, and energy-expenditure pathways.

The presence of both GLP-1R and GCGR activity makes the peptide relevant to experimental studies seeking to distinguish or integrate signaling from two related metabolic receptors.

Acylated Peptide Research

Survodutide contains a C18 di-acid-linked structural modification.

Long-chain fatty-acid conjugation is used in peptide design to alter protein binding, molecular disposition, and persistence relative to corresponding unmodified peptide sequences.

This makes the compound relevant to structure–activity and peptide-engineering research in addition to receptor pharmacology.

Survodutide vs Tirzepatide in Research

The phrase survodutide vs tirzepatide describes a comparison between two different multi-receptor peptide designs.

Survodutide is primarily characterized as a:

• GLP-1 receptor agonist
• Glucagon receptor agonist

Tirzepatide is characterized principally through:

• GLP-1 receptor agonism
• GIP receptor agonism

They therefore share GLP-1R activity but differ in their second major receptor target.

This distinction is more scientifically useful than ranking the compounds as “better” or “worse,” because their structures, receptor profiles, pharmacology, and experimental evidence differ.

What Is Survodutide?

Researchers asking what is survodutide are referring to the investigational acylated peptide also known as BI 456906.

It is designed to activate both GLP-1R and GCGR and has been investigated through cell-based assays, animal models, receptor pharmacology experiments, and controlled clinical research involving pharmaceutical preparations.

For Protide Health, the compound is supplied solely as laboratory research material and is not represented as a pharmaceutical preparation.

Survodutide Peptide Benefits: What the Evidence Shows

Searches for survodutide peptide benefits can blur the distinction between clinical drug-development research and independently supplied laboratory materials.

The scientifically appropriate research findings include observations involving:

• GLP-1R activation
• GCGR activation
• cAMP signaling
• Pancreatic experimental models
• Hepatic metabolic pathways
• Energy-expenditure models
• Food-intake research
• Amino-acid metabolism
• FGF21-associated biomarkers

Clinical trials of pharmaceutical BI 456906 have also evaluated metabolic endpoints in defined participant populations, but those findings should not be interpreted as benefits of the Protide Health research product.

Survodutide Dosage Searches and Research Use

The phrase survodutide dosage refers to human pharmaceutical-use questions and is not applicable to this laboratory research material.

Protide Health does not provide human dosing, administration, injection, titration, treatment schedules, or clinical-use recommendations.

Published clinical protocols use specifically manufactured pharmaceutical preparations under controlled study conditions and should not be converted into instructions for laboratory research products.

Research Limitations

Research involving Survodutide includes recombinant receptor assays, isolated cells, pancreatic-islet systems, animal models, and human clinical trials using investigational pharmaceutical formulations.

Important limitations include:

• Cell-based receptor activity does not establish human outcomes.
• Animal metabolic findings cannot automatically be extrapolated to people.
• Clinical-trial findings relate to specific investigational pharmaceutical preparations and protocols.
• Dual receptor activation does not establish the same response across every tissue or experimental system.
• Differences in formulation and peptide quality can affect experimental results.
• Clinical efficacy findings do not establish efficacy for independently supplied research material.

Protide Health therefore positions this peptide exclusively for qualified laboratory investigation.

Literature & Citation Index

BI 456906: Discovery and Preclinical Pharmacology of a Novel GCGR/GLP-1R Dual Agonist

Year: 2022
PMID: 36356832
Research Context: Cell-based receptor activation, cAMP signaling, pancreatic models, GCGR/GLP-1R target engagement, and animal metabolic research.

Phase I Studies of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906

Year: 2023
PMID: 36527386
DOI: 10.1111/dom.14948
Research Context: Early controlled clinical investigation of pharmaceutical BI 456906.

Glucagon and GLP-1 Receptor Dual Agonist Survodutide for Obesity: Phase 2 Trial

Journal: The Lancet Diabetes & Endocrinology
Year: 2024
PMID: 38330987
DOI: 10.1016/S2213-8587(23)00356-X
Research Context: Randomized pharmaceutical-development trial evaluating Survodutide in adults with overweight or obesity.

Dose-Response Effects of Survodutide in People With Type 2 Diabetes

Year: 2024
PMID: 38095657
Research Context: Controlled phase II investigation of pharmaceutical Survodutide in a defined clinical population.

Related Protide Health Research Products

Researchers examining separate peptide systems can review the P21 10mg research peptide for a structurally and mechanistically different research model.

The Oxytocin 10mg research peptide provides another distinct peptide system for receptor and molecular-signaling investigation.

Researchers may also examine Buffered NAD+ research material when comparing peptide research with non-peptide biochemical research compounds.

These products have different structures, receptor targets, and experimental applications and should not be treated as mechanistically interchangeable.

Frequently Asked Questions

What is Survodutide?

Survodutide is an acylated 29-residue synthetic peptide also known as BI 456906. It has been developed as a dual agonist of the GLP-1 receptor and glucagon receptor.

What receptors does Survodutide target?

The principal experimentally characterized targets are GLP-1R and GCGR. Both are class B G protein-coupled receptors with signaling that commonly involves intracellular cyclic AMP.

What is the Survodutide peptide sequence?

The verified modified sequence is commonly represented as:

H-Ac4c-QGTFTSDYSKYLDERAAKDFI-X-WLESA-NH₂

where Ac4c is 1-aminocyclobutane-1-carboxylic acid and X contains the fatty-acid-linked modification.

What does Survodutide research investigate?

Research has examined receptor activation, cAMP signaling, pancreatic responses, hepatic metabolic pathways, amino-acid metabolism, energy-balance models, and other GLP-1R/GCGR-associated endpoints.

How does Survodutide differ from Tirzepatide?

Survodutide combines GLP-1R and GCGR activity, whereas Tirzepatide principally combines GLP-1R and GIPR activity. Their secondary receptor targets are therefore different.

What purity does Protide Health specify?

The supplied product specification states 99% purity, with HPLC-MS verification and third-party testing.

What form is the product supplied in?

It is supplied as 10mg of white to off-white lyophilized powder in a 3mL vial.

Is Survodutide intended for human use?

No. Protide Health supplies this material exclusively for biochemical, analytical, receptor-signaling, in-vitro, and qualified preclinical research.

Laboratory Terms & Compliance

Laboratory Research Use Only

This product is supplied exclusively for laboratory research, analytical testing, in-vitro studies, preclinical research, and qualified scientific experimentation.

It is not intended for human or veterinary consumption, diagnostic use, therapeutic use, medical treatment, weight-loss treatment, metabolic treatment, or clinical administration.

No human dosage, dosing, administration, injection, titration, or preparation instructions are provided.

The purchaser is responsible for appropriate laboratory handling, storage, and use in accordance with applicable institutional, federal, state, and local requirements.

For research use only.